EPIGENOMICS AG |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.89 EUR | -.--% |
|
+8.31% | -.--% |
| Apr. 30 | Epigenomics AG Announces Jens Ravens Leaves as Executive Board Member | CI |
| Mar. 14 | Epigenomics AG Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| Sales 2022 | 485K 525K | Sales 2023 | 339K 367K | Capitalization | 1.61M 1.75M |
|---|---|---|---|---|---|
| Net income 2022 | -12M -12.99M | Net income 2023 | -4M -4.33M | EV / Sales 2022 | -4.8 x |
| Net cash position 2022 | 9.28M 10.05M | Net Debt 2023 | 9.78M 10.59M | EV / Sales 2023 | 33.6 x |
| P/E ratio 2022 |
-0.57
x | P/E ratio 2023 |
-0.36
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 66.77% |
More Fundamentals
* Assessed data
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Frederic Hilke
IRC | Investor Relations Contact | - | - |
Annett Dietrich
HRO | Human Resources Officer | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Helge Lubenow
CHM | Chairman | 56 | 16-05-24 |
Jochen Hummel
BRD | Director/Board Member | 54 | Feb. 04 |
Alexander Link
BRD | Director/Board Member | 53 | 20-05-31 |
Epigenomics AG is a Germany-based molecular diagnostics company focused on blood-based detection, prognosis and monitoring of cancers using deoxyribonucleic acid (DNA) methylation technology. It develops and commercializes blood-based diagnostic products across multiple cancer indications. The Company's main product is Epi proColon, a blood test for colorectal cancer screening. Along with the blood-based tests the Company offers services related to research, product development, regulatory approval and manufacturing of in-vitro diagnostic (IVD) products. It also offers Epi proLung, a blood-based test that detects the presence of lung cancer in blood plasma. The Company is present in Europe and the United States.
Calendar
2024-09-29
- Q2 2024 Earnings Release
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -38.92% | 8.34B | |
| +1.92% | 3.37B | |
| -10.21% | 2.04B | |
| -29.79% | 1.77B | |
| -21.12% | 1.66B | |
| +12.21% | 976M | |
| +29.92% | 814M | |
| -7.42% | 707M | |
| -26.33% | 532M |
- Stock Market
- Equities
- ECX Stock
- ECX Stock
